DISC: CD10/CALLA [56C6] Antibody

Common Uses By Pathologists:

Apical surface staining only: well differentiated carcinoma of colon, pancreas, prostate (Am J Clin Pathol 2000;113:374)
Diffuse cytoplasmic or membranous / Golgi staining pattern: adenocarcinoma (poorly differentiated), endometrial stromal sarcoma, melanoma, renal cell carcinoma, urothelial carcinoma

Acute lymphoblastic leukemia (ALL):
One of first markers to identify leukemic cells in children (hence its name)
Found on ALL cells which derive from pre-B lymphocytes

Bladder:
Present in 40%, strongly correlates with grade and stage (Diagn Pathol 2009;4:38, Am J Clin Pathol 2005;124:371)

Breast:
Marker of myoepithelial cells (Mod Pathol 2002;15:397), mammary myofibroblastoma (Virchows Arch 2007;450:727); but also rarely invasive ductal carcinoma, papilloma (J Clin Pathol 2007;60:958), benign stroma, sarcoma NOS (Diagn Pathol 2013 Jan 28;8:14)
Values may change post-chemotherapy (Indian J Cancer 2013;50:46)
Helps differentiate collagenous spherulosis (CD10+, HHF35+) from adenoid cystic carcinoma (CD10-, HHF35-, Pathol Res Pract 2012;208:405)

Ectopic prostate:
Used with PSA, PSAP to confirm diagnosis in uterus and vagina (Am J Surg Pathol 2006;30:209)

Endometrial stromal tumors:
May differentiate CD10+ endometrial stromal tumors from smooth muscle tumors, which are usually CD10- (Mod Pathol 2001;14:465), but not always (Mod Pathol 2002;15:923)

Endometriosis:
May be useful in diagnosis, except in cervix (Adv Anat Pathol 2004;11:310)

Gynecologic tumors:
Mesonephric remnants and tumors are CD10+
CD10 differentiates metastatic renal cell carcinoma (CD10+, Am J Surg Pathol 2003;27:178) from primary clear cell carcinoma (CD10-)

Hepatocellular carcinoma vs. non-hepatocellular carcinoma:
CD10+ is 52 – 68% sensitive and > 95% specific with canalicular pattern (Am J Surg Pathol 2001;25:1297, Am J Surg Pathol 2002;26:978), although another study recommends use of HepPar1, MOC31 and pCEA, but not CD10 (Mod Pathol 2002;15:1279)

Kidney
Distinguish renal cell carcinoma, clear cell type, eosinophilic variant (CD10+) from chromophobe carcinoma, eosinophilic variant or oncocytoma (both CD10-, Appl Immunohistochem Mol Morphol 2012;20:454)

Lymphoma: angioimmunoblastic T cell (AITL):
Distinguish AITL (CD10+, Mod Pathol 2011;24:993) at nodal and extranodal sites other than bone marrow from other T cell lymphomas (CD10-, Am J Surg Pathol 2004;28:54, Hum Pathol 2005;36:784), but benign T cells may also be CD10+ (Mod Pathol 2003;16:879)

Lymphoma: Burkitt:
CD10+ confirms diagnosis, but must exclude CD10+ diffuse large B cell lymphoma (Am J Clin Pathol 2012;137:665, Am J Clin Pathol 2010;133:718)

Lymphoma: diffuse large B cell:
Marker for germinal center phenotype (also HGAL, bcl6, CD38), usually considered a favorable prognostic factor (Mod Pathol 2005;18:1113, J Hematop 2009;2:187), but see Am J Clin Pathol 2001;116:183 (CD10+bcl2+ tumors have poorer survival), Virchows Arch 2004;445:545 (no difference in survival)

Lymphoma: follicular:
CD10+ may confirm diagnosis of primary (Am J Clin Pathol 2002;117:291), or secondary spread (Hum Pathol 2013;44:1328), but:
high grade follicular lymphomas and interfollicular infiltrates may be CD10- (Am J Clin Pathol 2001;115:862)
other lymphomas may be CD10+, including angioimmunoblastic T cell , Burkitt , diffuse large B cell lymphoma , mantle cell (Appl Immunohistochem Mol Morphol 2010;18:103), marginal zone (J Clin Pathol 1999;52:849), rare CD5+ CD10+ lymphomas (Am J Clin Pathol 2003;119:218, Arch Pathol Lab Med 2001;125:951)

Microvillous inclusion disease:
Strong CD10+ cytoplasmic staining in enterocytes (Am J Surg Pathol 2002;26:902, Orphanet J Rare Dis 2006 Jun 26;1:22) or colonic biopsies (Am J Surg Pathol 2010;34:970 ) vs. linear brush border staining of enterocytes and negative colonic staining in normals

Pancreas:
Confirm diagnosis of solid and papillary neoplasm (CD10+, Am J Surg Pathol 2000;24:1361)
Differentiates mucinous cystic neoplasms (CD10+ / CK20+) from intraductal papillary mucinous neoplasm of branch duct type (CD10- / CK20-, Pancreas 2009;38:558)

Skin tumors:
Staining patterns may differentiate basal cell carcinoma-epithelial staining, trichoblastoma-peritumoral stromal staining (Int J Dermatol 2009;48:713), squamous cell carcinoma-strong stromal staining (Iran J Med Sci 2013;38:100)
Differentiates atypical fibroxanthoma (diffuse membranocytoplasmic staining) from spindle cell melanoma and sarcomatoid squamous cell carcinoma (CD10-, J Cutan Pathol 2010;37:744)

Vascular tumors:
Differentiates metastatic renal cell carcinoma (CD10+, Mod Pathol 2005;18:788) from hemangioblastoma (usually CD10-, rarely focal staining-Diagn Pathol 2012 Apr 12;7:39)
Epithelioid hemangioendothelioma can have strong / diffuse CD10+ and mimic metastatic renal cell carcinoma (Arch Pathol Lab Med 2009;133:1965)